A 58-year-old man presents with fatigue and splenomegaly. Complete blood count shows WBC 85,000/μL with left shift, Hb 9.2 g/dL, and platelets 120,000/μL. Peripheral blood smear reveals myelocytes and metamyelocytes predominating. Which investigation is most specific for confirming chronic myeloid leukemia?

Explanation

## Philadelphia Chromosome as the Gold Standard **Key Point:** The Philadelphia chromosome (t(9;22) translocation resulting in BCR-ABL1 fusion gene) is the pathognomonic cytogenetic abnormality in CML and is present in >95% of cases. Its detection is diagnostic and mandatory for CML confirmation. ## Why BCR-ABL1 Detection is Most Specific **High-Yield:** BCR-ABL1 is: - Present in virtually all CML cases (95–99%) - Absent in other chronic leukemias and myeloproliferative disorders - Detectable by FISH (fluorescence in situ hybridization), PCR (most sensitive), or conventional cytogenetics - Prognostically and therapeutically critical (guides tyrosine kinase inhibitor selection) ## Comparison of Investigations in CML Diagnosis | Investigation | Utility in CML | Specificity | |---|---|---| | **Bone marrow aspiration** | Shows myeloid predominance, left shift; non-specific | Low — seen in other myeloproliferative disorders | | **BCR-ABL1 (FISH/PCR)** | **Diagnostic; identifies Philadelphia chromosome** | **Highest — pathognomonic** | | **Flow cytometry** | Excludes lymphoid malignancies; not diagnostic for CML | Low — phenotype overlaps with reactive myelosis | | **Conventional cytogenetics** | Detects t(9;22) but slower than FISH/PCR | High, but less sensitive than molecular methods | **Clinical Pearl:** In the modern era, reverse-transcriptase PCR (RT-PCR) for BCR-ABL1 transcript is the gold standard because it is: - Highly sensitive (detects minimal residual disease) - Quantitative (allows monitoring of treatment response) - Rapid (results in 24–48 hours) ## Diagnostic Algorithm for CML ```mermaid flowchart TD A[Suspected CML: elevated WBC, left shift, splenomegaly]:::outcome A --> B[Peripheral blood smear + CBC]:::action B --> C{Myeloid predominance?}:::decision C -->|Yes| D[Perform BCR-ABL1 testing]:::action D --> E{BCR-ABL1 positive?}:::decision E -->|Yes| F[CML confirmed]:::outcome E -->|No| G[Consider other myeloproliferative disorder]:::outcome C -->|No| H[Reconsider diagnosis]:::action ``` **Warning:** Do not rely solely on bone marrow morphology or cytochemical stains (e.g., myeloperoxidase) — these are supportive but not diagnostic. BCR-ABL1 detection is mandatory.